Log In
Print
BCIQ
Print
Print this Print this
 

omarigliptin (MK-3102)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionOnce-weekly, oral dipeptidyl peptidase-4 (DPP-4; CD26) inhibitor
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of ActionDipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today